MITONAFIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H15N3O4
Molecular Weight	313.308
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)CCN1C(=O)C2=CC=CC3=C2C(=CC(=C3)[N+]([O-])=O)C1=O

InChI

InChIKey=XXVLKDRPHSFIIB-UHFFFAOYSA-N

InChI=1S/C16H15N3O4/c1-17(2)6-7-18-15(20)12-5-3-4-10-8-11(19(22)23)9-13(14(10)12)16(18)21/h3-5,8-9H,6-7H2,1-2H3

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8913845 | https://www.ncbi.nlm.nih.gov/pubmed/9157079

Mitonafide is a nitro-containing antitumor drug. Mitonafide participated in clinical trials phase II in colorectal cancer patients, however, the results have shown that the drug was not active and induced severe myelotoxicity. Besides, the drug was involved in phase II for the patients with non-small cell lung cancer (NSCLC), where it was not active in spite of the safe administration. Information about the current development of this drug is not available.

Approval Year

PubMed

Title	Date	PubMed
Design, synthesis, and biological evaluation of substituted naphthalene imides and diimides as anticancer agent.	2009-12-10	19954251
A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition.	1998-04-14	9548739

Patents

Sample Use Guides

In Vivo Use Guide

All but one received a 120-hour (5-day) continuous infusion of Mitonafide at a starting dose of 200 mg/m2/day every 3 weeks

Route of Administration: Intravenous

Name

Type

Language

MITONAFIDE

Official Name

English

NSC-300288

Preferred Name

English

mitonafide [INN]

Common Name

English

1H-BENZ(DE)ISOQUINOLINE-1,3(2H)-DIONE, 2-(2-(DIMETHYLAMINO)ETHYL)-5-NITRO-

Systematic Name

English

N-(2-(DIMETHYLAMINO)ETHYL)-3-NITRONAPHTHALIMIDE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C582